-transparent.png){kind=logo}
Anti-CD20 monoclonal antibodies: historical and future perspectives. 2010
Sean H Lim, and
Stephen A Beers, and
Ruth R French, and
Peter W M Johnson, and
Martin J Glennie, and
Mark S Cragg
Tenovus Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton SO16 6YD, UK.
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.
Related Publications
Sean H Lim, and
Stephen A Beers, and
Ruth R French, and
Peter W M Johnson, and
Martin J Glennie, and
Mark S Cragg
November 2016,
Biotechnology advances,
Sean H Lim, and
Stephen A Beers, and
Ruth R French, and
Peter W M Johnson, and
Martin J Glennie, and
Mark S Cragg
March 2011,
Blood,
Sean H Lim, and
Stephen A Beers, and
Ruth R French, and
Peter W M Johnson, and
Martin J Glennie, and
Mark S Cragg
April 2017,
Expert review of neurotherapeutics,
Sean H Lim, and
Stephen A Beers, and
Ruth R French, and
Peter W M Johnson, and
Martin J Glennie, and
Mark S Cragg
September 2013,
Blood reviews,
Sean H Lim, and
Stephen A Beers, and
Ruth R French, and
Peter W M Johnson, and
Martin J Glennie, and
Mark S Cragg
January 2018,
Human vaccines & immunotherapeutics,
Sean H Lim, and
Stephen A Beers, and
Ruth R French, and
Peter W M Johnson, and
Martin J Glennie, and
Mark S Cragg
August 2008,
Current opinion in immunology,
Sean H Lim, and
Stephen A Beers, and
Ruth R French, and
Peter W M Johnson, and
Martin J Glennie, and
Mark S Cragg
September 2007,
Molecular immunology,
Sean H Lim, and
Stephen A Beers, and
Ruth R French, and
Peter W M Johnson, and
Martin J Glennie, and
Mark S Cragg
February 2013,
Expert opinion on biological therapy,
Sean H Lim, and
Stephen A Beers, and
Ruth R French, and
Peter W M Johnson, and
Martin J Glennie, and
Mark S Cragg
January 2021,
Biologicals : journal of the International Association of Biological Standardization,
Sean H Lim, and
Stephen A Beers, and
Ruth R French, and
Peter W M Johnson, and
Martin J Glennie, and
Mark S Cragg
February 2019,
Immunotherapy,
